Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an inverse dose response and a miss

Read the full 418 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers